Award
National Institute of Arthritis and Musculoskeletal and Skin Diseases 1R61AR085647-01
Veverimer to decrease net acid excretion and bone resorption in adults with osteopenia: a dose-finding randomized controlled trial
Recipient
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Award Amount
$331,051.00
Ceiling
$331,051.00
Awarded
July 31, 2025
Identifier
1R61AR085647-01
NIH grant awarded to study the safety and efficacy of veverimer in adults with osteopenia, focusing on dose-finding to reduce net acid excretion and bone resorption.
Description
This is a Phase 1 dose-finding study to evaluate the safety and efficacy of veverimer in adults with osteopenia who consume acid-producing diets. The study aims to identify the optimal dose of veverimer to reduce net acid excretion and assess its impact on bone resorption and formation.